Molecular Variants of the Precore, Core, and Core Promoter Regions of Hepatitis B Virus, and Their Clinical Significance
Peter Karayiannis
Department of Medicine, Imperial College London, London, UK
Search for more papers by this authorWilliam F. Carman
Fast Track Diagnostics, Junglinster, Luxembourg
Search for more papers by this authorHoward C. Thomas
Department of Medicine, Imperial College London, London, UK
Search for more papers by this authorPeter Karayiannis
Department of Medicine, Imperial College London, London, UK
Search for more papers by this authorWilliam F. Carman
Fast Track Diagnostics, Junglinster, Luxembourg
Search for more papers by this authorHoward C. Thomas
Department of Medicine, Imperial College London, London, UK
Search for more papers by this authorHoward C. Thomas BSc, PhD, FRCP, FRCPath, FMedSci
Emeritus Professor of Hepatology, Department of Medicine, Imperial College London, London, UK
Search for more papers by this authorAnna S.F. Lok MD
Alice Lohrman Andrews Research Professor in Hepatology, Director of Clinical Hepatology, Professor of Internal Medicine, Associate Chair for Clinical Research, Department of Internal Medicine, University of Michigan Health System, Ann Arbor, MI, USA
Search for more papers by this authorStephen A. Locarnini MBBS, BSc(Hons), PhD, FRCPath
Head, Research & Molecular Development, Victorian Infectious Diseases Reference Laboratory, Melbourne, VIC, Australia
Search for more papers by this authorArie J. Zuckerman MD, DSc, FRCP, FRCPath, FMedSci
Emeritus Professor of Medical Microbiology, Formerly Principal and Dean, Royal Free Hospital School of Medicine
Search for more papers by this authorSummary
HBV is highly evolved. It has a small and compact genome that makes very efficient use of its nucleotide sequence. Many regions are highly conserved, even between different hepadnaviruses. Yet the potential for significant change is also present. The precore or core gene and basal core promoter (BCP) variants, which reduce or abrogate HBeAg production, usually appear at the beginning of the seroconversion phase from HBeAg to anti-HBe. The gradual removal of the tolerogenic effect of HBeAg leads to the “awakening” of the immune response. Precore and basal core promoter variants have been associated with fulminant hepatitis, but host factors are also implicated. Resolution of the mechanisms by which these variants are selected, their effects on HBV replication, and their pathogenicity has been hampered by the absence of a reliable and robust cell culture system, and the use of viral strains with additional sequence changes in many studies.
References
- Beck J, Nassal M. Hepatitis B virus replication. World J Gastroenterol 2007; 13: 48–64.
- Ou J-H, Laub O, Rutter WJ. Hepatitis B virus gene function: the precore region targets the core antigen to cellular membranes and causes the secretion of the e antigen. Proc Natl Acad Sci USA 1986; 83: 1578–1582.
- Milich DR, Jones JE, Hughes JL, et al. Is a function of the secreted hepatitis B e antigen to induce immunologic tolerance in utero? Proc Natl Acad Sci USA 1990; 87: 6599–6603.
- Bottcher B, Wynne SA, Crowther RA. Determination of the fold of the core protein of hepatitis B virus by electron cryomicroscopy. Nature 1997; 386: 88–91.
- Pollack JR, Ganem D. An RNA stem-loop structure directs hepatitis B virus genomic RNA encapsidation. J Virol 1993; 67: 3254–3263.
- Yaginuma K, Koike K. Identification of a promoter region for 3.6-kilobase mRNA of hepatitis B virus and specific cellular binding protein. J Virol 1989; 6: 2914–2920.
- Yu X, Mertz J. Promoters for synthesis of the pre-C and pregenomic mRNAs of human hepatitis B virus are genetically distinct and differentially regulated. J Virol 1996; 6: 8719–8726.
- Hadziyannis SJ, Lieberman HM, Karvountzis MG, Shafritz D. Analysis of liver disease, nuclear HBeAg, viral replication and hepatitis B virus in liver and serum of HBeAg vs antiHBe positive chronic hepatitis B virus infection. Hepatology 1983; 3: 652–662.
- Karayiannis P, Fowler MJF, Lok ASF, Greenfield C, Monjardino J, Thomas HC. Detection of serum HBV-DNA by molecular hybridisation: correlation with HBeAg/anti-HBe status, racial origin, liver histology and hepatocellular carcinoma. J Hepatol 1985; 1: 99–106.
-
Carman WF,
Jacyna MR,
Hadziyannis S, et al.
Mutation preventing formation of e antigen in patients with chronic HBV infection.
Lancet
1989;
ii:
588–591.
10.1016/S0140-6736(89)90713-7 Google Scholar
- Chu CM, Karayiannis P, Fowler MJF, et al. Natural history of chronic hepatitis B virus infection in Taiwan: studies of hepatitis B virus DNA in serum. Hepatology 1985; 5: 431–434.
- Tsai SL, Chen PJ, Lai MY, et al. Acute exacerbations of chronic type B hepatitis are accompanied by increased T cell responses to hepatitis B core and e antigens. J Clin Invest 1992; 89: 87–96.
- Waters JA, O Rourke S, Schlict HJ, Thomas HC. Cytotoxic T cell responses in patients with chronic hepatitis B undergoing HBe antigen/antibody seroconversion. Clin Exp Immunol 1995; 102: 314–319.
- Chisari FV, Ferrari C. Hepatitis B virus immunopathogenesis. Annu Rev Immunol 1995; 13: 29–60.
- Hadziyannis SJ, Vassilopoulos D. Immunopathogenesis of hepatitis B e antigen negative chronic hepatitis B infection. Antiviral Res 2001; 52: 91–98.
- Chu Cj, Keeffe EB, Han SH, et al. Prevalence of HBV precore/core promoter variants in the United States. Hepatology 2003; 38: 619–628.
- Carman WF, Fagan EA, Hadziyannis S, et al. Association of a pre-core genomic variant of HBV with fulminant hepatitis. Hepatology 1991; 14: 219–222.
- Kusakabe A, Tanaka Y, Mochida S, et al. Case-control study for the identification of virological factors associated with fulminant hepatitis B. Hepatol Res 2009; 39: 648–656.
- Inoue J, Ueno Y, Wakui Y, et al. Enhanced replication of hepatitis B virus with frameshift in the precore region found in fulminant hepatitis patients. J Infect Dis 2011; 204: 1017–1025.
- Alexopoulou A, Karayiannis P, Hadziyannis SJ, et al. Whole genome analysis of hepatitis B virus from four cases of fulminant hepatitis: genetic variability and its potential role in disease pathogenicity. J Viral Hepat 1996; 3: 173–181.
- Karayiannis P, Alexopoulou A, Hadziyannis S, et al. Fulminant hepatitis associated with hepatitis B e virus antigen-negative infection: importance of host factors. Hepatology 1995; 22: 1628–1634.
- Okamoto H, Tsuda F, Akahane Y, et al. Hepatitis B virus with mutation in the core promoter for the e antigen negative phenotype in carriers with antibody to e antigen. J Virol 1994; 68: 8102–8110.
- Aiba N, McGervey MJ, Waters J, et al. The precore sequence of hepatitis B virus is required for nuclear localization of the core protein. Hepatology 1997; 26: 1311–1317.
- Lamberts C, Nassal M, Vellajen I, et al. Precore-mediated inhibition of hepatitis B virus progeny DNA synthesis. J Virol 1993; 67: 3756–3762.
- Hasegawa K, Huang J, Rogers SA, et al. Enhanced replication of a hepatitis B virus mutant associated with an epidemic of fulminant hepatitis. J Virol 1994; 68: 1651–1659.
- Bollyky PL, Yasmin M, Holmes E, et al. Viruses from unrelated fulminant hepatitis B cases cluster in phylogenetically distinct lineages, each containing unique motifs of nucleotide and HBx variants which have increased transcriptional activity in vitro. J Hepatol 1997; 26(Suppl 1): 67.
- Trautwein C, Schrem H, Tillman HL, et al. Hepatitis B virus mutations in the preS genome before and after liver transplantation. Hepatology 1996; 24: 482–488.
- Buckwold VE, Xu Z, Chen M, et al. Effects of a naturally occurring mutation in the hepatitis B virus basal core promoter on precore gene expression and viral replication. J Virol 1996; 6: 5845–5851.
- Moriyama K, Okamoto H, Tsuda F, et al. Reduced precore transcription and enhanced core-pregenome transcription of hepatitis B virus DNA after replacement of the precore-core promoter with sequences associated with e antigen-seronegative persistent infections. Virology 1996; 6: 269–280.
- Laras A, Koskinas J, Hadziyannis SJ. In vivo suppression of precore mRNA synthesis is associated with mutations in the hepatitis B virus core promoter. Virology 2002; 295: 86–96.
- Sterneck M, Kalinina T, Günther S, et al. Functional analysis of HBV genomes from patients with fulminant hepatitis. Hepatology 1998; 6: 1390–1397.
- Chun YK, Kim JY, Woo HJ, et al. No significant correlation exists between core promoter mutations, viral replication, and liver damage in chronic hepatitis B infection. Hepatology 2000; 32: 1154–1162.
- Li J, Xu Z, Zheng Y, et al. Regulation of hepatocyte nuclear factor 1 activity by wild-type and mutant hepatitis B virus X proteins. J Virol 2002; 76: 5875–5881.
- Qin Y, Tang X, Garcia T, et al. Hepatitis B virus genotype C isolates with wild-type core promoter sequence replicate less efficiently than genotype B isolates but possess higher virion secretion capacity. J Virol 2011; 85: 10167–10177.
- Chan HLY, Hussain M, Lok AS. Different hepatitis B virus genotypes are associated with different mutations in the core promoter and precore regions during hepatitis B e antigen seroconversion. Hepatology 1999; 6: 976–984.
- Liu Y, Zhong Y, Zou Z, et al. Features and clinical implications of hepatitis B virus genotypes and mutations in basal core promoter/precore region in 507 chinese patients with acute and chronic hepatitis B. J Clin Virol 2010; 47: 243–247.
- Fang Z-L, Ling R, Wang SS, et al. HBV core promoter mutations prevail in patients with hepatocellular carcinoma from Guangxi, China. J Med Virol 1998; 6: 18–24.
- Lee JH, Han Kl, Lee JM, Park JH, Kim HS. Impact of hepatitis B virus (HBV) x gene mutations on hepatocellular carcinoma development in chronic HBV infection. Clin Vaccine Immunol 2011; 18: 914–921.
- Bai X, Zhu Y, Jin Y, et al. Temporal acquisition of sequential mutations in the enhancer II and basal core promoter of HBV in individuals at high risk for hepatocellular carcinoma. Carcinogenesis 20011; 32: 63–68.
- Parekh S, Zoulim F, Ahn SH, et al. Genome replication, virion secretion, and e antigen expression of naturally occurring hepatitis B virus core promoter mutants. J Virol 2003; 77: 6601–6612.
- Ren X, Xu Z, Liu Y, et al. Hepatitis B virus genotypes and basal core promoter/precore mutations are associated with hepatitis B-related acute-on-chronic liver failure without pre-existing liver cirrhosis. J Viral Hepat 2010; 17: 887–895.
- Yan T, Li K, Li F, et al. T1846 and A/G1913 are associated with acute on chronic liver failure in patients infected with hepatitis B virus genotypes B and C. J Med Virol 2011; 83: 996–1004.
- Hou J, Lin Y, Waters J, Wang Z, et al. Detection and significance of a G1862T variant of hepatitis B virus in Chinese patients with fulminant hepatitis. J Gen Virol 2002; 83: 2291–2298.
- Laskus T, Rakela J, Tong MJ, et al. Naturally occurring hepatitis B virus mutants with deletions in the core promoter region. J Hepatol 1994; 20: 837–841.
- Fukuda R, Xuanthanh N, Ishimura N, et al. X gene and precore region mutations in the hepatitis B virus genome in persons positive for antibody to hepatitis B e antigen: comparison between asymptomatic healthy carriers and patients with severe chronic active hepatitis. J Infect Dis 1995; 172: 1191–1197.
- Kramvis A, Kew MC, Bukofzer S. Hepatitis B virus precore mutants in serum and liver of Southern African Blacks with hepatocellular carcinoma. J Hepatol 1998; 6: 132–141.
-
Laskus T,
Rakela J,
Steers JL, et al.
Precore and contiguous regions of hepatitis B virus in liver transplantation for end-stage hepatitis B.
Gastroenterology
1994;
6:
1774–1780.
10.1016/0016-5085(94)90820-6 Google Scholar
-
Kohno K,
Nishizono A,
Terao H, et al.
Reduced transcription and progeny virus production of hepatitis B virus containing an 8-bp deletion in basic core promoter.
J Med Virol
2000;
61:
15–22.
10.1002/(SICI)1096-9071(200005)61:1<15::AID-JMV3>3.0.CO;2-V CAS PubMed Web of Science® Google Scholar
- Liang TJ, Blum HE, Wands JR. Characterization and biological properties of a hepatitis B virus isolated from a patient without hepatitis B virus serologic markers. Hepatology 1990; 12: 204–212.
- Carman WF, Ferrao M, Lok ASF, et al. Pre-core sequence variation in Chinese isolates of hepatitis B virus. J Infect Dis 1992; 165: 127–133.
- Yuen MF, Sablon E, Yuan HJ, et al. Relationship between the development of precore and core promoter mutations and hepatitis B e antigen seroconversion in patients with chronic hepatitis B virus. J Infect Dis 2002; 186: 1335–1338.
- Nie H, Evans AA, London WT, Block TM, Ren XD. Quantitative dynamics of hepatitis B basal core promoter and precore mutants before and after HBeAg seroconversion. J Hepatol 2012; 56: 795–802.
- Bertoletti A, Costanzo A, Chisari FV, et al. Cytotoxic T lymphocyte response to a wild type hepatitis B virus epitope in patients chronically infected by variant viruses carrying substitutions within the epitope. J Exp Med 1994; 180: 933–943.
- Chuang WL, Omata M, Ehata T, et al. Precore mutations and core clustering mutations in chronic hepatitis B virus infection. Gastroenterology 1993; 104: 263–271.
- Ehata T, Omata M, Yokosuka O, et al. Variations in codons 84–101 in the core nucleotide sequence correlate with hepatocellular injury in chronic hepatitis B virus infection. J Clin Invest 1992; 89: 332–338.
- Carman WF, Thursz M, Hadziyannis S, et al. HBeAg negative chronic active hepatitis: HBV core mutations occur predominantly in known antigenic determinants. J Viral Hepat 1995; 2: 77–84.
- Alexopoulou A, Karayiannis P, Hadziyannis SJ, et al. Emergence and selection of HBV variants in an anti-HBe positive patient persistently infected with quasi-species. J Hepatol 1997; 26: 748–753.
- Carman WF, Boner WF, Fattovich G. HBV core protein mutations are concentrated in B cell epitopes in progressive disease and T helper cell epitopes in clinical remission. J Infect Dis 1997; 175: 1093–1100.
- Akarca US, Lok ASF. Naturally occurring core-gene-defective hepatitis B viruses. J Gen Virol 1995; 76: 1821–1826.
- Gunther S, Baginski S, Kissel H, et al. Accumulation and persistence of hepatitis B virus core gene deletion mutants in renal transplant patients are associated with end-stage liver disease. Hepatology 1996; 24: 751–758.
- Marinos G, Torre F, Günther S, et al. Hepatitis B virus variants with core gene deletions in the evolution of chronic hepatitis B infection. Gastroenterology 1996; 111: 183–192.
- Yuan TT, Lin MH, Qiu SM, et al. Functional characterization of naturally occurring variants of human hepatitis B virus containing the core internal deletion mutation. J Virol 1998; 72: 2168–2176.
- Bhat RA, Ulrich PP, Vyas GN. Molecular characterization of a new variant of hepatitis B virus in a persistently infected homosexual man. Hepatology 1990; 11: 271–276.
- Terre S, Petit MA, Brechot C. Defective hepatitis B virus particles are generated by packaging and reverse transcription of spliced viral RNAs in vivo. J Virol 1991; 65: 5539–5543.
- Webster GJ, Bertoletti A. Control or persistence of hepatitis B virus: the critical role of initial host-virus interactions. Immunol Cell Biol 2002; 80: 101–105.
- Rehermann B, Fowler P, Sidney J, et al. The cytotoxic T lymphocyte response to multiple hepatitis B virus polymerase epitopes during and after acute viral hepatitis. J Exp Med 1995; 181: 1047–1058.
- Guidotti LG, Rochford R, Chung J, et al. Viral clearance without destruction of infected cells during acute HBV infection. Science 1999; 284: 825–829.
- Lai ME, Solinas A, Mazzoleni AP, et al. The role of pre-core hepatitis B virus mutants on the long-term outcome of chronic hepatitis B virus hepatitis. A longitudinal study. J Hepatol 1994; 20: 773–781.
- Bertoletti A, Sette A, Chisari FV, et al. Natural variants of cytotoxic epitopes are T-cell receptor antagonists for antiviral cytotoxic T cells. Nature 1994; 369: 407–410.
- Milich DR. Do T cells see the hepatitis B core and e antigens differently? Gastroenterology 1999; 116: 765–768.
- Hadziyannis SJ. Interferon alpha therapy in HBeAg-negative chronic hepatitis B: new data in support of long-term efficacy. J Hepatol 2002; 36: 280–282.
- Rizzetto M. Efficacy of lamivudine in HBeAg-negative chronic hepatitis B. J Med Virol 2002; 66: 435–451.
- Cho SW, Hahm KB, Kim JH. Reversion from precore/core promoter mutants to wild-type hepatitis B virus during the course of lamivudine therapy. Hepatology 2000; 32: 1163–1169.